CEL-SCI Corporation (CVM)
|52 Week Range||1.04-3.33|
|1y Target Est||-|
|DCF Unlevered||CVM DCF ->|
|DCF Levered||CVM LDCF ->|
|Debt / Equity||94.80%||Buy|
Upgrades & Downgrades
Latest CVM news
Why Is CEL-SCI (CVM) Stock Down 23% Today?
18 July 2023
CEL-SCI (NYSEMKT: CVM ) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering. CEL-SCI is offering up 2.5 million shares of its common stock at a pr...
CEL-SCI's Multikine - Potential 21st Century Game-Changing Cancer Drug On The Horizon
30 September 2022
CEL-SCI demonstrated significant clinical benefits for head & neck cancer patients. In the lower-risk group, there was a 14.1% absolute survival improvement.
3 Penny Stocks to Watch With Above Average Volume Today
18 April 2022
Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
CEL-SCI, Poised For Success, Is A Seriously Big Opportunity (Part II)
11 August 2021
In our last article, we provided ten reasons why we believe FDA approval of CEL-SCI's drug Multikine and concomitant multibillion dollar valuation is highly likely. This article addresses the critics'...
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
14 July 2021
CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which can treat 155,000 newly diagnosed advanced primary head and neck cancer patients per year globally. Five-year...
CEL-SCI Stock Increased 8.5%: Why It Happened
7 July 2021
The stock price of CEL-SCI Corporation (NYSEAMERICAN: CVM) increased 8.5%. This is why it happened.
Why CEL-SCI Stock Soared Today
7 July 2021
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporat...
5 July 2021
New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM). Such invest...
Discussion of Results of CEL-SCI's Phase 3 Trial Is Now Available
2 July 2021
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.